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Abstract
Background: Although much is known about the regulation of osteoclast (OC) formation and
activity, little is known about OC senescence. In particular, the fate of of OC seen after 1,25-
(OH)2D3 administration in vivo is unclear. There is evidence that the normal fate of OC is to
undergo apoptosis (programmed cell death). We have investigated the effect of short-term
application of high dose 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on OC apoptosis in an
experimental rat model.
Methods: OC recruitment, augmentation and apoptosis was visualised and quantitated by staining
histochemically for tartrate resistant acid phosphatase (TRAP), double staining for TRAP/ED1 or
TRAP/DAPI, in situ DNA fragmentation end labelling and histomorphometric analysis.
Results: Short-term treatment with high-dose 1,25-(OH)2D3 increased the recruitment of OC
precursors in the bone marrow resulting in a short-lived increase in OC numbers. This was rapidly
followed by an increase in the number of apoptotic OC and their subsequent removal. The
response of OC to 1,25-(OH)2D3 treatment was dose and site dependent; higher doses producing
stronger, more rapid responses and the response in the tibiae being consistently stronger and more
rapid than in the vertebrae.
Conclusions: This study demonstrates that (1) after recruitment, OC are removed from the
resorption site by apoptosis (2) the combined use of TRAP and ED1 can be used to identify OC
and their precursors in vivo (3) double staining for TRAP and DAPI or in situ DNA fragmentation
end labelling can be used to identify apoptotic OC in vivo.
Background
1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), the major
pharmacologically active metabolite of vitamin D3 plays a
central role with regards to calcium homeostasis. It is
known induce bone resorption in mouse and rat bone in
vitro[20] and stimulates bone resorption in vivo in both in-
tact and parathyroidectomized animals [42,35]. In short-
term organ cultures of bone, the major effect of 1,25-
(OH)2D3 appears to be an increase in osteoclastic activity
[20], without increasing osteoclast (OC] number. This
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stimulation of activity is unlikely to be a direct effect as
mature OC do not express the vitamin D receptor (VDR]
[30] and in isolated OC systems, no direct effects of 1,25-
(OH)2D3 on bone resorption has been seen [29]. In con-
trast, co-cultures of osteoblast-like cells and OC respond
to 1,25-(OH)2D3 with an increase in resorption suggest-
ing an indirect, osteoblast-mediated, effect [29]. Consist-
ent with this, osteoblasts have been shown to express the
VDR [40] and are known to respond to 1,25-(OH)2D3
treatment with an increase in the production of bone ac-
tive cytokines such as IL-1 and IL-6 [12]. Cells of the
monocyte-macrophage family and a number of lymphoid
cell lines also express the VDR suggesting that 1,25-
(OH)2D3 may also stimulate OC recruitment from hae-
matopoietic precursors [26].
The origin of the OC has been much disputed, however, it
is now widely accepted that OC are derived from mono-
nuclear cells that originate in the bone marrow or other
hematopoietic organs and migrate to the bone via vascu-
lar routes [13,23,27]; reviewed in [46,1]. The effect of
1,25-(OH)2D3 on OC recruitment and differentiation has
been studied widely in vitro, but, due to the lack of suitable
model systems, not in vivo (reviewed by [1,41,37]). The
increased bone resorption in response to administration
of 1,25-(OH)2D3in vivo is clearly associated with an in-
crease in the number of OC [43], however, the low fre-
quency of OC precursors in the bone marrow and the
difficulty in unequivocally identifying these OC precur-
sors greatly restricts their study in vivo. Thus, the precise
pathway by which OC are recruited and differentiate in
vivo has not been clearly demonstrated.
Although much is known about factors regulating OC for-
mation and OC activity, little information is available
about factors involved in OC senescence. In particular, the
fate of the increased numbers of OC seen after administra-
tion of 1,25-(OH)2D3in vivo is unclear. There is growing
evidence that the normal fate of OC is to undergo apopto-
sis (programmed cell death). Previous studies have indi-
cated that apoptotic OC can be identified at reversal sites,
however, because the activity of individual bone remodel-
ling units is asynchronous, this is a difficult process to
study in vivo.
We have developed a model system in which a rapid, pre-
dictable and reproducible increase in OC numbers is in-
duced in vivo by the administration of high doses of 1,25-
(OH)2D3. This increase in OC number is then followed by
an equally rapid and reproducible apoptosis-mediated de-
crease in OC numbers. This model has allowed us to in-
vestigate the cellular events in the bone marrow and
locally along the trabecular bone surface during the re-
cruitment, differentiation and subsequent death of OC
and their precursors.
Materials and Methods
Animal procedures
All animals procedures were carried out according to cur-
rent Home Office regulations and all necessary licenses
had been obtained. Male wistar rats were allowed free ac-
cess to a pelleted standard chow, containing 1.0% calcium
and 0.65% phosphate and 4.5 IU Vitamin D3/g, and tap
water and the animals were acclimated for 1 week prior to
the start of all experiments. In order to determine the ef-
fect of 1,25-(OH)2D3 on OC recruitment, differentiation
and subsequent apoptosis, a series of 4 experiments were
performed in which rats were treated with differing doses
of 1,25-(OH)2D3 and then killed at various time-points
afterwards. In experiment 1, six 200 g male Wistar rats
were allocated into two groups and were injected subcuta-
neously (s.c.) with either vehicle or 10 µg 1,25-(OH)2D3
/kg body weight (BW) on day 1 of the study, and then
killed on day 2 by cervical dislocation. In experiment 2,
six 200 g male Wistar rats were allocated into two groups
and injected s.c. with either vehicle or with 10 µg 1,25-
(OH)2D3 /kg BW on days 1, 2 and 3 of the study and then
killed on day 4. In experiment 3, thirty 200 g male Wistar
rats were allocated into two groups and injected s.c. with
either vehicle or 2 µg 1,25-(OH)2D3 /kg BW on days 1, 2
and 3 of the study. Three rats from each group were then
killed on days 4, 6, 9, 13 and 17. In experiment 4, sixty
male Wistar rats with a mean initial body weight of 285 g,
were allocated into two weight-matched groups and were
s.c. injected with either vehicle or 0.2 µg 1,25-(OH)2D3 /
kg BW on days 1, 2 and 3 of the study. Five rats of each
group were killed on days 4, 6, 8, 10, 12 and 14 by cervical
dislocation. The reason for the small groups in Exp 1, 2 &
3 was that preliminary experiments had shown that these
were sufficient provide statistically significant effects at
these high doses.
Histology: Sample processing
After the rats were sacrificed the left proximal tibiae and
the fourth lumbar vertebral bodies were removed (with
the exception of Exp 1 where vertebrae were not sampled),
dissected free of soft tissue and fixed in PLP fixative (2%
paraformaldehyde containing 0.075 M lysine and 0.01 M
sodium periodate solution) for 24 hr at 5°C as previously
described [28]. After fixation, specimens were washed for
12 hours at 5°C in each of the following series of solu-
tions: 0.01 M PBS containing 5% glycerol, 0.01 M PBS
containing 10% glycerol, 0.01 M PBS containing 15%
glycerol. The specimens were then decalcified in EDTA-G
solution (14.5 g EDTA, 15 ml of glycerol, 85 ml distilled
water, and solid sodium hydroxide added until a final pH
of 7.3 was reached) for 10–14 days at 5°C as previously
described [31]. Progression of decalcification was checked
by micro-X ray. The decalcified tissues were washed se-
quentially at 5°C for 12 hr in (a) 15% sucrose and 15%
glycerol in PBS, (b) 20% sucrose and 10% glycerol in PBS,BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/16
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(c) 20% sucrose and 5% glycerol in PBS, (d) 20% sucrose
in PBS; 10% sucrose in PBS, (e) 5% sucrose in PBS and (f)
100% PBS as previously described [5]. Tissues were dehy-
drated in graded alcohols and embedded in low-melting-
point paraffin. 5 µm sections were cut at frontal for tibiae
and at sagittal for vertebrae. The sections were stained
with hematoxylin and eosin (HE), histochemically for tar-
trate resistant acid phosphatase (TRAP), immunohisto-
chemically for ED1, double stained for TRAP/ED1 or
TRAP/4',6-diamidino-2-phenylindole (DAPI) or by in situ
DNA end-labelling of apoptotic OC using Klenow
FragEL™ kit (ISEL).
Histology: Tartrate resistant acid phosphatase histochem-
istry
Osteoclastic cells were identified by staining histochemi-
cally for TRAP following a modified version of a previous-
ly described method. Briefly, the sections were
deparaffinized and preincubated for 20 minutes in sodi-
um acetate (50 mM) and potassium sodium tartrate (40
mM) buffer (pH 5.0) and then incubated for a further 15
minutes at room temperature (RT) in the same buffer con-
taining naphthol AS-MX phosphate (2.5 mg/ml) (Sigma)
and fast garnet GBC (0.5 mg/ml, Sigma). As a negative
control, some sections were incubated in the above medi-
um with fast garnet GBC but without naphthol AS-MX
phosphate. After washing with distilled water, the sections
were counterstained with Vector methyl green nuclear
counterstain (Vector laboratories, Peterborough, UK) and
mounted in Kaiser's glycerol jelly.
Histology: ED1 Immunostaining
Cells of the monocytic lineage were identified by staining
for ED1 using the avidin-biotin-peroxidase complex
(ABC) immunoperoxidase technique. The tissue sections
were preincubated for 30 minutes at 37°C with 2% Bovine
testicular hyaluronidase in PBS. Endogenous peroxidase
activity was blocked by immersing the sections in 3% hy-
drogen peroxide for 10 min, followed by washing in run-
ning water for 5 min and then flooding with TBS for 5
min. The sections were then incubated with 20% normal
goat serum for 30 min at RT to block non-specific binding.
The sections were incubated overnight at RT with the
mouse anti-rat monocytes/macrophages monoclonal an-
tibody (ED1, Serotec Ltd, Oxford, England) diluted 1: 100
in 1% BSA. As a negative control, Mouse IgG1 negative
control (DAKO, Denmark) was substituted for the prima-
ry antibody. After washing, the sections were incubated
with secondary antibody (biotinylated goat anti-mouse
IgG, Fab special, Sigma, diluted 1:300 TBS) for 30 min at
RT. The sections were then washed as above and incubat-
ed with Vectastain Elite ABC reagent (Vector laboratories,
Peterborough, UK) for 30 min at RT. After washing as
above, grey pigmentation was produced by 5–10 min
treatment with Vector SG substrate (Vector laboratories,
Peterborough, UK). After washing with distilled water, the
sections were counterstained with methyl green and
mounted with Kaiser's glycerol jelly.
Histology: Identification of apoptotic osteoclasts
Apoptotic OC were identified morphologically by the fol-
lowing features: 1) detachment from resorption surface;
2) chromatin condensation and nuclear fragmentation; 3)
cytoplasmic condensation; 4) strong TRAP staining to
confirm osteoclastic origin [21]. Using these criteria, ap-
optotic OC in TRAP stained sections of could easily be dis-
tinguished from viable OC (fig. 1a,1b,1c,1d). In order to
confirm the presence of apoptotic OC, they were also as-
sessed for nuclear fragmentation after DAPI staining and
by in situ DNA end-labelling. The sections were stained
with DAPI after TRAP histochemistry by incubating the
sections in 1 µg/ml DAPI in TBS for 10 minutes. After
washing with distilled water the sections were air dried
and mounted in citifluor. Free 3'-OH groups generated by
endonucleases released during apoptosis were end-la-
belled using a Frag EL™ DNA fragmentation detection Kit
(Calbiochem-Novabiochem LTD, UK) according to the
manufacturers instructions with the exception that Vector
SG substrate (Vector laboratories, Peterborough, UK) was
substituted for diaminobenzidene. The sections were
counterstained with methyl green and mounted in Kai-
ser's glycerol jelly. All three methods produced compara-
ble results in terms of changes in the numbers of
apoptotic OC in response to 1,25-(OH)2D3 and so for
quantitative purposes, apoptotic OC were identified ac-
cording to their morphological characteristics.
Histology: Quantitative histomorphometry
Numbers of TRAP positive (+ve) bone marrow cells
(BMC) and ED1 +ve BMC were counted in the bone mar-
row immediately below the tibial secondary spongiosae.
OC parameters were measured in the secondary spongi-
osae of the left proximal tibia and the fourth lumbar ver-
tebral body using a semiautomatic system
(Osteomeasure, OsteoMetrics, Inc. GA, USA) and an Ol-
ympus microscope with a drawing attachment. Static his-
tomorphometric parameters were measured in sections
stained for TRAP. The following primary parameters were
determined in five fields of view (× 200) in one section per
rat: tissue area, bone perimeter, number of TRAP +ve
BMC, number of ED1 +ve BMC, OC number, OC perime-
ter and the number of apoptotic OC. The values obtained
from these 5 fields were then averaged and used as the val-
ue for that particular animal. From the primary data, the
following static parameters were calculated:-
Number of TRAP +ve BMC/tissue area = N.TRAP +ve
BMC/T.Ar (#/mm2)BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/16
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Figure 1
Apoptotic OC (a-d). (a) An early stage TRAP +ve apoptotic OC that has detached from the resorption surface. Its cyto-
plasm is condensed and it is surrounded by space due to cell shrinkage (× 1000). (b) An early stage apoptotic OC with cytoplas-
mic TRAP (red) and nuclear ISEL (grey) staining (× 1000). (c) Late stage apoptotic OC with intense cytoplasmic TRAP staining
and condensed, fragmented nuclei which are positive for ISEL (× 1000). (d) A typical apoptotic OC with intense cytoplasmic
TRAP staining, a condensed cytoplasm and condensed positive nuclei stained with DAPI (× 1000). Expression of TRAP/ED1
in bone marrow cells (e-h). (e) In the tibia of vehicle treated rats there were only occasional TRAP +ve BMC (× 200). (f) A
single treatment with 10 µg/kg 1,25-(OH)2D3 gave rise to a significant increase in the number of TRAP +ve BMC (× 200). (g)
TRAP +ve BMC located in the bone marrow (× 1000). (h) TRAP/ED1 +ve BMC located in the bone marrow (× 1000): TRAP
expression in the secondary spongiosa (day 4) (i-l). Tibiae from (i) vehicle and (j) 1,25-(OH)2D3 treated rats (2 µg/kg)
and vertebrae from (k) vehicle and (l) 1,25-(OH)2D3 treated rats (2 µg/kg) (magnification: × 200). Expression of TRAP in
the secondary spongiosae (day 6) (m-p). Tibiae from vehicle (m) and 1,25-(OH)2D3 treated rats (2 µg/kg) (n) or verte-
brae from vehicle (o) and 1,25-(OH)2D3 treated rats (2 µg/kg) (p) (magnification: × 200): Expression of TRAP/ED1 in bone
tissue (q-t). ED1 immunostaining show (q) ED1 +ve viable OC (× 1000). Double staining for TRAP and ED1 show (r) both
positive viable OC for TRAP (red) and ED1 (grey). ED1 is richest in the clear zone of OC (× 400). (s) TRAP +ve viable OC
(× 1000), and (t) TRAP +ve OC together with periosteal cells weakly +ve for TRAP (× 400).BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/16
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Number of ED1 +ve BMC/tissue area = N.ED1 +ve BMC/
T.Ar (#/mm2)
Number of OC/tissue area = N.OC/T.Ar (#/mm2)
Number of OC/bone perimeter = N.OC/B.Pm (#/mm)
OC perimeter/bone perimeter = OC.Pm/B.Pm, (%)
Number of apoptotic OC/tissue area = Ap.OC/T.AR, (#/
mm2)
Statistical analysis
Statistical comparisons were made using the non-para-
metric Mann-Whitney test. P values of less than 0.05 were
considered significant. The data are presented as means ±
S.E.
Results
Changes in ED1 +ve and TRAP/ED1 +ve bone marrow cell 
numbers
In the bone marrow, ED1 staining was found to be local-
ised to large macrophages and small monocyte-like cells.
The numbers of ED1 +ve BMC were increased significantly
in 1,25-(OH)2D3 treated rats on day 2 in Exp 1, day 4 in
Exp 2 and on day 6 in Exp 3 (table 1). TRAP +ve BMC were
found only occasionally in the bone marrow of control
animals however, in Exp 1 on day 2 of the study their
numbers were increased in the 1,25-(OH)2D3 treated rats
10 fold compared to vehicle controls. No significant dif-
ference in the numbers of TRAP +ve BMC was observed
between vehicle and 1,25-(OH)2D3 treated rats in Exp 2
and Exp 3 (table 1). It was found that all TRAP +ve BMC
were also ED1 +ve and morphologically appeared to be
large macrophage-like cells. However, not all ED1 +ve
BMC were also TRAP +ve and apart from day 2 in Exp 1,
the number of ED1 +ve cells always exceeded the number
of TRAP +ve cells (table 1). There appeared to be more
TRAP +ve BMC in the bone marrow at a distance from the
metaphysis than in the bone marrow of the secondary
spongiosae. A number of these TRAP +ve mononuclear
cells were found around or within bone marrow sinusoids
or capillaries (fig. 1e,1f,1g,1h). Treatment with 3 ×  0.2 µg/
kg 1,25-(OH)2D3 (Exp 4) had no significant effect on the
numbers of ED1 +ve and TRAP/ED1 +ve bone marrow cell
numbers (data not shown).
As well as macrophages, monocytes and TRAP +ve BMC,
most OC also expressed ED1. It was found that the OC ex-
pressed ED1 more frequently in the primary spongiosa
than in the secondary spongiosa and that the ED1 staining
was most intense in the clear zone of the OC.
Changes in osteoclast numbers
The changes in OC-related parameters are summarised in
tables 2 & 3. The changes in OC numbers were dependent
on the dose of 1,25-(OH)2D3 used with higher doses pro-
ducing both stronger and quicker responses. The adminis-
tration of 3 daily injections of 10 µg 1,25-(OH)2D3/kg
BW had no significant effect on OC numbers in the tibiae,
but caused an increase in the number of vertebral OC by
125% on day 4 of the study. The administration of 3 daily
injections of 2 µg 1,25-(OH)2D3/kg BW resulted in a 48%
increase in the number of OC in the tibiae and 81% in the
vertebrae on day 4 of the study, and a decrease in the
number of OC by 61% in the tibiae and 52% in vertebrae
on day 6 of the study (fig. 1i,1j,1k,1l). The administration
of 3 daily injections of 0.2 µg 1,25-(OH)2D3/Kg BW re-
sulted in an increased in the number of the OC by 37% in
the tibiae on day 6 of the study, and a decrease in the
number of OC by 48% in the tibiae on day 8 of the study
(fig. 1m,1n,1o,1p). At this dose however, no effect was
seen in the vertebrae. In general, it was found that the re-
sponse of the tibiae to 1,25-(OH)2D3 was stronger and
quicker than that of the vertebrae. In all cases, OC param-
eters were increased for only a short time and rapidly re-
turned to basal levels.
Changes in numbers of apoptotic osteoclast
As shown above, the number of viable OC increased after
treatment with 1,25-(OH)2D3 but then decreased within
a short period of time. This appeared to be due to the rap-
id onset of OC apoptosis after 1,25-(OH)2D3-induced re-
cruitment (tables 2 & 3, fig. 1a,1b,1c,1d). In Exp 3, the
number of apoptotic OC was increased significantly in
both vertebrae and tibiae on day 4 of the study and re-
mained above control values for a further two days, but re-
turned to control values in both the vertebrae and tibiae
by day 9 of the study. As with OC recruitment, the num-
bers of apoptotic OC was also dependent on the dose of
1,25-(OH)2D3administered with higher doses of 1,25-
(OH)2D3 induced more OC to enter apoptosis more rap-
idly. It was also noted that fewer apoptotic OC number
appeared in vertebrae than in tibiae, and that apoptosis
was delayed compared to tibiae.
Comparison of sections stained for TRAP activity with
those stained using ISEL revealed that fewer apoptotic OC
were identified using ISEL than with the classical morpho-
logical features of apoptosis. This is presumably because
ISEL identifies OC at an earlier stage of apoptosis before
they detached from the resorption surface (fig. 1b). On
the other hand, some apoptotic bodies of OC are not
identified by ISEL because of their lack of condensed nu-
clei. This characteristic of late stage apoptotic OC was con-
firmed by double staining for TRAP and DAPI. This shows
that in the later stages of OC apoptosis, the nuclei and cy-BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/16
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toplasm may split into fragments of various sizes, which
may or may not contain nuclear fragments.
Discussion
It has been shown in vitro that the increase in OC seen af-
ter treatment with 1,25-(OH)2D3 is due to the differenti-
ation of monocytic OC precursors and the activation of
mature OC. As mature OC do not possess a VDR this is
unlikely to be a direct effect and is probably mediated os-
teoblastic cells or marrow stromal cells [1,41,37]. The
study of these events in vivo has been hampered by a lack
of specific markers which can identify OC and their pre-
cursors in vivo. OC are usually identified histologically by
staining for TRAP, however, as other cells, e.g. osteoblasts
and osteocytes, also express TRAP activity in vivo this is not
100% specific [3]. This means that OC can only be identi-
fied using a combination of morphology, e.g. multinucle-
arity, and TRAP staining. To investigate the effects of 1,25-
(OH)2D3 on OC recruitment in vivo, we have used double
staining for both TRAP and ED1, a monoclonal antibody
ED1 directed against rat CD68 which reacts with periph-
eral monocytes and macrophages [8,2,22,8] and also OC
and their precursors [38]. Using this approach, it was pos-
sible to follow both the increase in monocytic cells in the
Table 1: Effect of 1,25-(OH)2D3 on the number of TRAP +ve and ED1 +ve Bone Marrow Cells
Exp Dose Time TRAP +ve BMC (#/mm2)E D 1  + v e  B M C  ( # / m m 2)
Vehicle 1,25-(OH)2D3 Vehicle 1,25-(OH)2D3
11   ×  10 µg/kg 2 d 1.60 ± 0.41 16.37 ± 4.53* 1.66 ± 0.33 16.67 ± 5.09*
23   ×  10 µg/kg 2 d 0.33 ± 0.16 0.44 ± 0.19 2.08 ± 0.45 4.58 ± 1.25*
33   ×  2 µg/kg 4 d 0.74 ± 0.13 0.67 ± 0.24 0.83 ± 0.33 1.46 ± 0.60
6 d 0.63 ± 0.21 0.56 ± 0.19 1.25 ± 0.33 11.04 ± 4.00*
9 d 0.59 ± 0.27 0.59 ± 0.19 0.83 ± 0.30 1.36 ± 0.28
13 d 0.56 ± 0.24 0.59 ± 0.24 1.36 ± 0.28 2.50 ± 1.18
17 d 0.74 ± 0.19 0.78 ± 0.14 1.25 ± 0.33 2.92 ± 0.79*
All values are means ± SE, *: P < 0.05.
Table 2: Effect of 1,25-(OH)2D3 on Osteoclastic parameters in rat tibial trabecular bone
Exp Dose Time N.Oc/T.Ar (#/mm2) N.Oc/B.Pm (#/mm) N.ApOc/T.Ar (#/mm2)
Vehicle 1,25-(OH)2D3 Vehicle 1,25-(OH)2D3 Vehicle 1,25-(OH)2D3
11   ×  10 µg/kg 1 d 63.1 ± 2.0 61.7 ± 2.9 6.0 ± 0.5 6.4 ± 0.8 0.7 ± 0.3 1.0 ± 0.6
23   ×  10 µg/kg 4 d 76.7 ± 2.4 65.7 ± 3.8 7.5 ± 0.1 6.3 ± 0.3 1.0 ± 0.6 11.7 ± 0.9*
33   ×  2 µg/kg 4 d 75.0 ± 6.3 111.0 ± 2.0* 7.0 ± 0.3 9.7 ± 5.3* 0.3 ± 0.3 10.3 ± 0.7*
6 d 85.1 ± 9.5 41.3 ± 12.9* 8.4 ± 0.5 3.2 ± 1.1* 1.0 ± 0.6 5.0 ± 0.6*
9 d 91.9 ± 10. 98.4 ± 9.8 8.8 ± 0.7 8.8 ± 0.6 0.7 ± 0.3 0.7 ± 0.3
13 d 9 81.1 ± 4.5 8.9 ± 1.2 6.7 ± 0.7 0.7 ± 0.3 0.3 ± 0.3
17 d 71.0 ± 5.3 73.9 ± 2.6 6.5 ± 0.2 6.5 ± 0.4 0.7 ± 0.3 1.0 ± 0.6
73.5 ± 2.2
43   ×  0.2 µg/kg 4 d 39.2 ± 4.9 33.4 ± 3.0 3.5 ± 0.3 3.9 ± 0.2 0.4 ± 0.2 0.6 ± 0.2
6 d 32.9 ± 2.4 45.1 ± 4.1* 3.8 ± 0.3 5.1 ± 0.7* 0.6 ± 0.2 1.0 ± 0.3
8 d 37.6 ± 5.6 23.4 ± 2.1* 5.2 ± 0.7 3.1 ± 0.2* 0.4 ± 0.2 1.6 ± 0.2*
10 d 35.5 ± 3.4 40.9 ± 3.5 5.2 ± 0.5 4.6 ± 0.6 0.4 ± 0.2 0.8 ± 0.4
12 d 36.9 ± 5.0 39.0 ± 7.9 4.6 ± 0.3 4.5 ± 0.4 0.4 ± 0.2 0.6 ± 0.2
14 d 41.1 ± 3.9 37.5 ± 1.3 5.7 ± 0.5 4.9 ± 0.4 0.2 ± 0.2 0.4 ± 0.2
All values are mean ± SE, *: P < 0.05BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/16
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bone marrow and their subsequent differentiation to OC
after treatment with 1,25-(OH)2D3 (fig. 1q,1r,1s,1t).
A 1,25-(OH)2D3 mediated transient increase in OC num-
bers and recruitment of OC precursors has been reported
previously [6], however, the temporal and dose depend-
ent effects of 1,25-(OH)2D3 on OC recruitment and dif-
ferentiation have never been studied in detail in vivo. In
this study we have used high doses of 1,25-(OH)2D3 to
induce a rapid and reproducible increase in the numbers
of OC precursors and OC followed by their subsequent
apoptosis mediated death. The results here show that
treatment with 1,25-(OH)2D3 leads to an increase in OC
numbers on the surface of trabecular bone which is pre-
ceded by an increase in the number of ED1 positive
mononuclear cells increased in the bone marrow. In addi-
tion, in rats given a single, very high, dose of 1,25-
(OH)2D3 (10 µg/kg), significant numbers of ED1/TRAP
+ve cells were seen in the bone marrow and some distance
from the bone surface. These ED1/TRAP +ve bone marrow
cells could be sub-divided into monocyte/macrophage-
like BMC, located mainly in the bone marrow at a dis-
tance from metaphysic and apoptotic bodies of OC which
had previously died with condensed nuclei or without nu-
clei. These results together, are consistent with the in vitro
findings that the first stage of 1,25-(OH)2D3 mediated os-
teoclastogenesis is the recruitment of monocytic bone
marrow cells. The appearance of TRAP +ve/ED1 +ve bone
marrow cells is also consistent with the suggestion that the
presence of bone surfaces are not absolutely necessary for
subsequent osteoclastic differentiation [34].
The various in vitro models developed over the last decade
to study OC differentiation have led to three alternative
hypotheses for OC differentiation: (1) independent devel-
opment from a specialised progenitor originating in the
GM-CFU compartment [17,18]; (2) divergence from the
M-CFU compartment [10,11]; or (3) late monocytes or
macrophages are direct precursors of OC [44,39]. The re-
sults here show that the increase in OC numbers was al-
ways associated with, or preceded by, an increase in the
number of ED1 +ve BMC. Due to the subsequent apoptot-
ic death of the newly induced OC, this increase in OC
numbers is transient, however, the increase in ED1 +ve
BMC numbers is maintained after the disappearance of
OC. The temparospatial relationship between the in-
creased numbers of ED1 +ve BMC, the TRAP +ve/ED1 +ve
BMC and the newly recruited OC, together with the find-
ing that most OC were also ED1 +ve, tends to support the
3rd hypothesis, that the newly recruited OC are derived
from monocytic BMC and that the increase in OC num-
bers is due to a general increase in monocyte numbers.
Previous studies have shown conflicting results in vivo,
finding that 1,25-(OH)2D3 results in an increase [47], a
decrease [14,36] or no change in bone resorption [33,15].
These inconsistencies may reflect the different doses ad-
ministered or the different time points and the sites ob-
served. Our results have shown that short-term treatment
with high dose 1,25-(OH)2D3 (2 µg/kg and above) result-
ed in an increase in OC parameters in both tibiae and ver-
tebrae whereas short-term treatment with a lower dose of
1,25-(OH)2D3 (0.2 µg/kg) increased OC parameters in
tibiae but not in vertebrae. Short-term treatment with
Table 3: Effect of 1,25-(OH)2D3 on osteoclastic parameters in fourth lumbar vertebral trabecular bone
Exp Dose Time N.Oc/T.Ar (#/mm2) N.Oc/B.Pm (#/mm) N.ApOc/T.Ar (#/mm2)
Vehicle 1,25-(OH)2D3 Vehicle 1,25-(OH)2D3 Vehicle 1,25-(OH)2D3
23   ×  10 µg/kg 4 d 33.9 ± 5.0 66.4 ± 5.5* 3.9 ± 0.7 7.7 ± 1.0* 04 . 6   ± 1.3*
33   ×  2 µg/kg 4 d 31.0 ± 1.7 56.3 ± 3.3* 3.5 ± 0.4 6.9 ± 0.4* 0.5 ± 0.3 3.1 ± 0.4*
6 d 35.0 ± 4.2 16.7 ± 0.6* 4.1 ± 0.5 3.3 ± 0.1* 0.7 ± 0.2 3.5 ± 0.3*
9 d 30.6 ± 7.3 33.9 ± 4.7 3.8 ± 0.8 3.9 ± 0.7 0.7 ± 0.2 0.7 ± 0.2
13 d 26.7 ± 2.4 46.9 ± 4.8* 2.9 ± 0.4 5.1 ± 0.3* 0.7 ± 0.2 1.2 ± 0.4
17 d 30.3 ± 5.0 44.0 ± 4.5 3.5 ± 0.3 4.6 ± 0.6 0.5 ± 0.2 1.0 ± 0.3
43   ×  0.2 µg/kg 4 d 28.8 ± 1.9 27.3 ± 1.9 3.0 ± 0.2 2.7 ± 0.2 0.2 ± 0.2 0
6 d 28.2 ± 1.5 27.1 ± 2.6 3.0 ± 0.1 3.0 ± 0.2 0.2 ± 0.2 0
8 d 26.9 ± 2.8 29.2 ± 2.2 2.9 ± 0.2 3.2 ± 0.4 0 0.4 ± 0.2
10 d 29.4 ± 2.4 31.7 ± 2.3 3.7 ± 0.1 3.1 ± 0.3 0.2 ± 0.2 0.4 ± 0.2
12 d 31.5 ± 2.7 32.5 ± 3.3 3.3 ± 0.3 3.6 ± 0.3 0.2 ± 0.2 0.2 ± 0.2
14 d 30.6 ± 3.2 29.8 ± 2.7 3.5 ± 0.3 3.5 ± 0.3 0 0.2 ± 0.2
All values are mean ± SE, *: P < 0.05BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/16
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high dose 1,25-(OH)2D3 resulted in a transient increase
in OC numbers followed by a decrease relative to control
animals. As most previous studies have only observed one
time point after treatment, it is quite possible that they
failed to observe key events in the recruitment and differ-
entiation of OC after treatment. These data are consistent
with those of Boyce & Weisbrode [6], in that treatment
with 1,25-(OH)2D3 resulted in a transient augmentation
followed by a decrease in OC parameters with the excep-
tion that they observed an earlier increase in OC parame-
ters than ours. This difference may be the result of
different levels of dietary calcium with high levels of die-
tary calcium being used in the experiments of Boyce and
Weisbrode and normal dietary calcium in our experi-
ments. In clinical studies assessing the effects of short-
term 1,25-(OH)2D3 treatment on calcium and bone me-
tabolism, no initial resorptive phase was observed
[15,4,16]. It is likely that this is due to the much lower
doses of 1,25-(OH)2D3 used in human studies.
The ultimate fate of OC after treatment with 1,25-
(OH)2D3 has never been studied in detail in vivo. In this
study we have shown that short-term treatment with high-
dose 1,25-(OH)2D3 induces an increase in OC number
which is subsequently followed by a rapid decrease due to
death by apoptosis. As with OC recruitment, higher doses
of 1,25-(OH)2D3 resulted in an earlier onset of apoptosis
and a higher percentage of apoptotic OC. Similarly, OC
apoptosis occurred earlier and in higher numbers in tibiae
compared to vertebrae. This site specific effect of 1,25-
(OH)2D3 may be due to differences in the blood supply
leading to a higher effective concentration of 1,25-
(OH)2D3 arriving at the tibiae or it may be due to differ-
ences in the numbers of OC precursors being present in
the marrow. To identify apoptotic OC we used a combina-
tion of histochemistry for TRAP and double staining for
TRAP and DAPI or ISEL. TRAP staining is essential to iden-
tify apoptotic OC as it is difficult to identify apoptotic OC
in HE or Giemsa stained sections and double staining for
TRAP and DAPI could be used to demonstrate chromatin
condensation and nuclear fragmentation. ISEL was used
to visualise DNA fragmentation, however, ISEL and mor-
phological studies identified slightly different popula-
tions of apoptotic OC, due to the presence of some late
stage apoptotic bodies without nuclei.
The mechanism of action underlying this increase in OC
numbers followed by their subsequent apoptosis remains
to be resolved and may involve systemic factors, local fac-
tors or a combination of the two. It is well established that
1,25-(OH)2D3 can induce osteoclast formation and activ-
ity in vitro[20,29,24] and it would seem likely that this is
also the case in vivo. Calcium homeostasis in vivo is
thought to be governed mainly by interactions between
1,25-(OH)2D3 and parathyroid hormone (PTH) with
PTH being the major factor responsible for maintaining
osteoclastic activity. This may explain the transient nature
of the osteoclastic response to 1,25-(OH)2D3 as we have
previously shown that short-term treatment with 1,25-
(OH)2D3 is followed by a transient decrease in serum
PTH [9]. This down-regulation of serum PTH may in turn
be due to either a direct effect of 1,25-(OH)2D3 or the hy-
percalcaemia seen shortly after treatment with 1,25-
(OH)2D3 [9].
The relationship between OC apoptosis and 1,25-
(OH)2D3 treatment is unclear. To date there have been no
studies published detailing the effects of 1,25-(OH)2D3,
PTH or their withdrawal on OC apoptosis suggesting that
they do not play a major role in the process. Consistent
with this, it has been shown previously that OC numbers
decrease after 1,25-(OH)2D3 treatment even when 1,25-
(OH)2D3 is not withdrawn [6]. The data here show that
OC apoptosis tended to closely parallel the 1,25-
(OH)2D3-induced OC activity suggesting that the degree
of OC apoptosis was related to the OC activity itself. A
great many growth factors including TGF-β , IGF, PDGF,
FGF and the BMPs are known to be stored in the bone ma-
trix and released during bone resorption [19] and it would
seem likely that the 1,25-(OH)2D3-induced apoptosis
may well be mediated by the release of one of these. To
support this, it has been shown that TGF-β  can induce ap-
optosis in OC in vitro and the induction of OC apoptosis
by oestrogen in vitro is also mediated by TGF-β  [21]. Fur-
thermore it has recently been shown that the OC apopto-
sis associated with periodontal tooth movement in vivo is
also associated with an increase in TGF-β  expression[32].
Further study is required to elucidate the biochemical
pathway that leads to apoptosis of OC following exposure
to 1,25-(OH)2D3. Nevertheless, the administration of
1,25-(OH)2D3 can induce a predictable and reproducible
increase in the number of apoptotic OC. This may be a
useful model for studying the regulation of OC apoptosis
in vivo.
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